Regulation FD Disclosure

Business Context and Reporting Period

Galecto, Inc. (Nasdaq: GLTO) filed this Current Report on Form 8-K dated September 29, 2022. The filing reports interim clinical results for the ongoing Phase 2a MYLOX-1 trial of GB2064, an oral LOXL2 inhibitor for patients with myelofibrosis who are ineligible, refractory, or intolerant to JAK inhibitor therapy.

The submitted metadata identifies Damora Therapeutics, Inc., but the filing itself identifies Galecto, Inc. as the registrant.

Key Financial and Operating Metrics

  • The filing does not provide revenue, net income, cash flow, margins, debt, liquidity, or other financial statement metrics.
  • GB2064 is administered at 1,000 mg twice daily for nine months.
  • The MYLOX-1 primary endpoint is safety and tolerability; secondary endpoints include bone marrow fibrosis and hematological parameters.
  • Sixteen patients had been dosed. Eight had completed or continued treatment, while eight had discontinued due to an adverse event or disease progression.

Material Changes and Clinical Results

  • The planned intermediate assessment evaluated five patients who had completed at least six months of treatment and had repeat bone marrow biopsies.
  • Four of five evaluable patients experienced at least a one-grade reduction in bone marrow collagen fibrosis.
  • All four patients with fibrosis reductions had stable hemoglobin, white blood cell counts, thrombocytes, and spleen volume during the six-month treatment period; none required transfusions.
  • Two patients entered the study extension phase based on clinical benefit assessed by their treating physicians.

Management Commentary, Risks, and Unusual Items

  • GB2064 had a generally acceptable tolerability profile to date, although the trial remains ongoing and the interim sample was limited to five evaluable patients.
  • The most common treatment-related adverse events were gastrointestinal and were generally manageable with standard therapy.
  • No treatment-related serious adverse events occurred among the five patients completing at least six months of treatment. Across the full trial population, the only possibly treatment-related serious adverse event reported was a fall.
  • The study is open-label and single-arm; the filing does not establish efficacy in a controlled comparison or provide final trial results.
  • The filing includes Regulation FD disclosure and an exhibit containing the September 29, 2022 press release. The disclosed information is not deemed filed for Exchange Act Section 18 liability purposes, except as expressly incorporated by reference.

Investor Verification Points

  • Verify the registrant identity and reconcile the metadata reference to Damora Therapeutics with the filing’s identification of Galecto, Inc.
  • Review the attached Exhibit 99.1 press release for any additional trial details or qualifications.
  • Monitor the full MYLOX-1 dataset, including the final nine-month results, safety outcomes, discontinuations, and statistical or clinical significance.
  • Confirm whether subsequent filings provide financial position, cash runway, funding needs, or potential effects of the GB2064 program on liquidity.
  • Assess the risks associated with the small, nonrandomized, open-label interim dataset and the possibility that later results may differ.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.